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る．Gilliland らは，遺伝子変異を ₂ つに分類し，細胞の
増殖・細胞死抑制を起こすclass I変異と，細胞分化を阻
害するclass II変異の ₂つが白血病生成に必要であるとし
















































































































Bone morphogenic protein recepor ₁ A
Osteopontin
CXCL₁₂/ CXCR ₄  interactions




c-Kit/ Stem cell factor
Cdc₄₂ and Rac proteins























































































JinらはCD₁₂₃（IL- ₃ 受容体受α鎖；IL- ₃ Rα）に対する
モノクローナル抗体が白血病細胞の骨髄への生着と増殖
を阻害することを示し₂₁），さらに白血病細胞を移植した
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　Hematopoietic stem cells (HSCs) reside in the bone marrow and are capable of generating all blood cells through 
their capacities for multilineage differentiation and self-renewal. Hematopoiesis is a sequential process of cell fate 
decision and differentiation emanating from HSCs. They undergo stepwise, hierarchical differentiation through 
multipotent progenitors, lineage-restricted progenitors, and immature blood cells, and eventually generate mature 
blood cells in all hematopoietic lineages in peripheral blood. Leukemia, a malignant tumor derived from immature 
hematopoietic progenitors, is thought to arise from leukemia-initiating cells (LICs) that possess self-renewal capacity 
similar to that of normal HSCs, and these LICs initiate and maintain the leukemic state. LICs are thought to give rise 
to other leukemic cells with less self-renewal potential. This is supported by the observation that most leukemic cells 
do not proliferate in vitro and only a fraction of leukemic cells form colonies in methylcellulose cultures. LICs are 
considered to be quiescent and chemo-resistant, serving as a reservoir of cells responsible for disease relapse. 
Identifying the precise character and behavior of LICs, as well as the molecular mechanisms for LIC initiation and 
maintenance, would help develop novel targeted therapies for LICs, eventually leading to better outcomes for 
leukemic patients.
